197 related articles for article (PubMed ID: 11502457)
21. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia.
Mohanty NK; Saxena S; Singh UP; Goyal NK; Arora RP
Urol Oncol; 2005; 23(6):383-5. PubMed ID: 16301113
[TBL] [Abstract][Full Text] [Related]
22. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
Walczak JR; Carducci MA;
Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
[TBL] [Abstract][Full Text] [Related]
23. Chemoprevention in prostate cancer.
Assikis V; Brawley OW
Curr Probl Cancer; 2004; 28(4):218-30. PubMed ID: 15318324
[No Abstract] [Full Text] [Related]
24. Chemoprevention of prostate cancer.
Kucuk O
Cancer Metastasis Rev; 2002; 21(2):111-24. PubMed ID: 12465750
[TBL] [Abstract][Full Text] [Related]
25. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
[TBL] [Abstract][Full Text] [Related]
26. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial.
Thompson IM; Coltman CA; Crowley J
Prostate; 1997 Nov; 33(3):217-21. PubMed ID: 9365551
[TBL] [Abstract][Full Text] [Related]
27. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
Goetzl MA; Holzbeierlein JM
Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
[TBL] [Abstract][Full Text] [Related]
28. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.
Grossfeld GD; Small EJ; Lubeck DP; Latini D; Broering JM; Carroll PR
Urology; 2001 Aug; 58(2 Suppl 1):56-64. PubMed ID: 11502450
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents.
Nelson WG; Wilding G
Urology; 2001 Apr; 57(4 Suppl 1):56-63. PubMed ID: 11295596
[TBL] [Abstract][Full Text] [Related]
30. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
Nguyen MM; Wang Z
Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of prostate cancer with finasteride.
Canby-Hagino ED; Brand TC; Hernandez J; Thompson IM
Expert Opin Pharmacother; 2006 May; 7(7):899-905. PubMed ID: 16634712
[TBL] [Abstract][Full Text] [Related]
32. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
[TBL] [Abstract][Full Text] [Related]
33. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
[TBL] [Abstract][Full Text] [Related]
34. [Chemoprevention of prostate cancer].
Djavan B; Thompson I; Michel MS; Waldert M; Seitz C
Urologe A; 2004 May; 43(5):557-61. PubMed ID: 15042290
[TBL] [Abstract][Full Text] [Related]
35. Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy.
Bostwick DG; Ramnani D; Cheng L
Urol Clin North Am; 1999 Aug; 26(3):465-79. PubMed ID: 10494285
[TBL] [Abstract][Full Text] [Related]
36. [Chemoprevention of prostate cancer. Current status].
Schmitz-Dräger BJ; Lümmen G; Schäfer RM
Urologe A; 2007 Jun; 46(6):611-5. PubMed ID: 17483928
[TBL] [Abstract][Full Text] [Related]
37. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.
Taneja SS; Smith MR; Dalton JT; Raghow S; Barnette G; Steiner M; Veverka KA
Expert Opin Investig Drugs; 2006 Mar; 15(3):293-305. PubMed ID: 16503765
[TBL] [Abstract][Full Text] [Related]
38. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
[TBL] [Abstract][Full Text] [Related]
39. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
Fujimoto N; Chang C; Nomura M; Matsumoto T
Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691
[TBL] [Abstract][Full Text] [Related]
40. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
